drugset / Trial / NCT05369312
Phase 1 Study of BPI-442096 in Advanced Solid Tumor Patients
Non-randomizedSequentialOpen-labelTreatment
Summary
A first-in-human study to evaluate the safety, tolerability and maximum tolerated dose (MTD) and establish the recommended phase 2 dose (RP2D) of BPI-442096, a SHP2 inhibitor, in patients with advanced solid tumors.
Timeline
- Start
- 2022-06
- Primary completion
- 2024-05-01
- Completion
- 2025-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BPI-442096 | Unknown | — | Oral |